Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIALE-M: Venetoclax + azacitidine maintenance in AML first remission after chemotherapy
jRCT2080225047Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by AbbVie Inc. Started Feb 2020; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080225047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225047.